早期干扰素治疗对转化为确定的多发性硬化症的影响:一项随机化研究
1Multiple Sclerosis Centre, Department of Neuroscience, IRCCS Ospedale S Raffaele, via Olgettina 60, 20132, Milan, Italy. g.comi@hsr.it
Lancet (London, England)
|May 30, 2001
概括
在早期多发性硬化症患者中,干扰素β-1a治疗显著减少了复发和疾病进展. 这种疗法改善了临床结果和磁共振成像 (MRI) 发现,提供了一个有前途的早期干预策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 多发性硬化症 (MS) 的活性被干扰素β降低.
- 早期多发性硬化症患者面临转化为临床确定的MS的高风险.
- 评估了干扰素β-1a对高风险患者复发发生的影响.
研究的目的:
- 评估干扰素β-1a在预防复发和疾病进展的疗效,在患者的第一个神经事件暗示MS.
- 评估早期干扰素β-1a治疗对临床和MRI结果的影响.
主要方法:
- 随机,双盲,安慰剂对照试验.随机,双盲,安慰剂对照试验.
- 22mcg的干扰素β-1a或安慰剂,每周一次,在2年内进行皮下注射.
- 每6个月进行一次临床评估;每12个月进行一次脑部核磁共振.
主要成果:
- 较少接受干扰素β-1a的患者转化为临床确定的MS (34%对45%,p=0.047).
- 与干扰素β-1a (569 vs. 252天,p=0.034) 相比,30%转化为明确的MS的时间更长.
- 观察到每年复发率显著降低 (0.33比0.43,p=0.045) 和减少MRI损伤负担.
结论:
- 早期的干扰素β-1a治疗在治疗多发性硬化症方面显示出显著的益处.
- 治疗对临床疾病活动和MRI检测到的病变都有积极的影响.
- 干扰素β-1a是一种有效的早期干预,用于患有MS转化高风险的患者.
相关概念视频
Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...

